Consistent with the observation with lung cancer cell lines expressing the mutant or the wild type p53 (Figure 1), the treatment with bortezomib resulted in degradation of the ectopically expressed p53R273H and accumulation of the wild type p53 protein (Supplementary Figure 2). Here, TP53 is linked to lung carcinoma.